All lobbying filings

PROFESSIONAL COMPOUNDING CENTERS OF AMERICA

Lobbying for PROFESSIONAL COMPOUNDING CENTERS OF AMERICA

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · Texas · House · Senate · $220,000.00 expenses · posted Jul 20, 2026

Official filing document

Bills named in this filing 5

HR 5316
Drug Shortage Compounding Patient Access Act of 2025
S 3794
SAFE Drugs Act of 2026
HR 6509
SAFE Drugs Act of 2025
S 3788
CLEAR LABELS Act
HR 8269
CLEAR LABELS Act

Lobbying activity 3

Budget/Appropriations

Agriculture appropriations spending bill; Department of Labor-Health and Human Services appropriations bill

Pharmacy

Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act

Medicare/Medicaid

Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.